News

Study: Timing of administration an oft-overlooked factor in drug delivery

In addition to being blockbuster drugs, Nexium, the Advair Diskus and Rituxan all have a half-life of less than 6 hours and target circadian genes, meaning that their efficacy could be influenced by the timing of their administration due to the so-called biological/molecular clock, according to University of Pennsylvania researchers.

CSL ties up with Enable Injections to market biologic delivery device

Plasma protein specialist CSL Behring has tied the knot with Ohio devicemaker Enable Injections to use Enable's technology for the delivery of treatments for chronic diseases. The development agreement will give CSL access to market the device.

Eye care company pSivida receives royalty payment, will spend it on pipeline

Eye care company pSivida will use the $25 million milestone payment for the recent FDA approval of sustained-release therapy Iluvien to fund its pipeline.

Microscale fibers may have many drug-delivery uses

Drug delivery researchers are probing the depths of nanotechnology. However, researchers at New York University have shown that the maxim "better is better" can be true in the drug-delivery world as well, due to the development of drug delivering fibers that are the diameter of spider silk.

Harvard team uses stem cells to deliver toxic doses to cancer cells

Researchers at Harvard have programmed stem cells embedded in a tumor to deliver a toxic dose of cytotoxins, killing the cancer cells from the inside.

BDSI aiming to develop injectable buprenorphine

BioDelivery Sciences International is partnering with Evonik to develop a formulation of buprenorphine that can be subcutaneously injected and provide continuous therapy for 30 days. BDSI will pursue an approval for opioid dependence in about three years, but also aims to develop a product for chronic pain in patients requiring continuous opioid therapy.

Pfizer to withdraw from partnership to develop tamper-proof oxycodone formulation

The prospects for Remoxy, the twice-rejected, investigational, extended-release oral formulation of oxycodone, look bleak. Pfizer is pulling out of a partnership with Durect to commercialize the candidate, after reviewing the results of 5 clinical trials conducted in response to the FDA's second complete response letter, issued in 2011.

Encapsulation of fecal matter achieved for treatment of infected colons

Fecal microbiota transplantation enables the reconstitution of gut bacteria, and has been proven effective to treat Clostridium difficile infections of the colon. But, as you can imagine, the nature of the active ingredient presents a tough drug delivery challenge. Luckily, the field is advancing.

Highland pulls in $25M for night-dosed morning ADHD treatment

Highland Therapeutics, a Toronto-based company with delayed-release technology for ADHD treatment, brought in $25 million to push its lead candidates through mid- and late-stage trials and prepare for commercialization.

Nanoparticle size: Smaller is better, up to a certain point

The optimal size of nanoparticles is 50 nanometers, smaller than the 100- to 200-nm ones deployed today, concludes a study by University of Illinois researchers.

Sanofi leads $11M Series A round for needle-free delivery company

Portal Instruments, a new Boston-based company, secured $11 million for its computerized needle-free drug delivery system via a Series A funding round led by Sanofi, Boston-based VC PBJ Capital and a major medical device company. It became only the third company to receive funding under Sanofi's Sunrise Initiative for early stage companies.

Encapsulated Alzheimer's, Parkinson's-treating growth factors implanted directly in the brain

Scientists in Spain have now developed small particles with the ability to encapsulate growth factors when implanted in the brain, which could ultimately reverse the effects of these diseases by spurring the growth of new, healthy neurons.

GSK exec stresses need to move away from 'fragmented' approach to drug delivery

Talking of breaking internal siloes has become a corporate-speak cliche. But in a speech that could be described as brutally honest, GlaxoSmithKlines' head of drug delivery nevertheless brought the importance of doing so to life during last week's Partnership Opportunities in Drug Delivery conference.

Alnylam releases data on its Phase II study of TTR-mediated amyloidosis patients

At the American Neurological Association's 2014 Annual Meeting in Baltimore, Alnylam released 6-month data on its Phase 2 open-label extension (OLE) study of patisiran (ALN-TTR02), a clinical-stage RNAi candidate for the treatment of TTR-mediated amyloidosis in patients with familial amyloidotic polyneuropathy.

Stealthy, DNA-based 'nano-cocoons' deliver cancer-killing payloads

Researchers at NC State University and the University of North Carolina have developed a DNA-based delivery vehicle capable of acting as a Trojan horse in cancer cells. Using DNA as a cage instead of synthetic materials makes the vehicle less toxic to healthy cells and allows for the attachment of precise targeting mechanisms.

Stem cell-derived beta cells deliver insulin in response to blood sugar levels

The self-regulation of insulin delivery is a long-sought goal in the field, spurring the development of closed-loop systems and an artificial pancreas for diabetics. But some researchers are aiming smaller, looking at a way to create stem cells en masse that can produce insulin in response to blood sugar levels.

Robert Langer talks science, business and how they intersect

BOSTON--Master scientist and entrepreneur Robert Langer offered his thoughts on those topics and their relationship to drug delivery to FierceDrugDelivery in his MIT office and later to the field at large at the Partnership Opportunities in Drug Delivery conference in Boston.

Intersect ENT says latest data on dissolving implants for chronic sinusitis are encouraging

Now-public Intersect ENT touted three studies in the International Forum of Allergy & Rhinology, saying the results of their clinical studies demonstrated the benefits of its Propel and investigational Resolve implants for use in patients following sinus surgery.

Drug delivery: Fertile ground for pharma-device company partnerships?

BOSTON--Whether through collaboration with academia or buyouts of smaller players, panelists at the Partnership Opportunities in Drug Delivery conference concurred that Big Pharma is increasingly looking externally for innovation and using its size and financial to power candidates through clinicial and onto the market.

Partnerships in Drug Delivery conference kicks off next week in Boston

The latest Partnership in Drug Delivery conference will kick off in Boston next week chaired by Roche Global Business Development Director Barbara Lueckel and with keynote speaker Robert Langer, MIT professor and biotech entrepreneur. FierceDrugDelivery will be on the scene and reporting next week with all the highlights.